Literature DB >> 19868919

THE SOLUBLE SPECIFIC SUBSTANCE OF PNEUMOCOCCUS : SECOND PAPER.

M Heidelberger1, O T Avery.   

Abstract

1. The method for the concentration and purification of the soluble specific substance of Pneumococcus has been improved. 2. Highly purified specific substance of Type II pneumococcus of polysaccharide nature is shown to be recovered essentially unchanged after precipitation by immune serum, by uranyl nitrate, by basic lead acetate, or by safranine. 3. Marked chemical differences are shown to exist between the specific substances of Type II and Type III pneumococcus, although both react as polysaccharides. 4. The weight of evidence is considered to be in favor of the view that the specific substances of Pneumococcus Types II and III are actually polysaccharide derivatives. 5. The immunological significance of the foregoing view is discussed.

Entities:  

Year:  1924        PMID: 19868919      PMCID: PMC2128576          DOI: 10.1084/jem.40.3.301

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  3 in total

1.  The Azine and Azonium Compounds of the Proteolytic Enzymes. I.

Authors:  H R Marston
Journal:  Biochem J       Date:  1923       Impact factor: 3.857

2.  IMMUNOLOGICAL RELATIONSHIPS OF CELL CONSTITUENTS OF PNEUMOCOCCUS.

Authors:  O T Avery; M Heidelberger
Journal:  J Exp Med       Date:  1923-06-30       Impact factor: 14.307

3.  THE ELABORATION OF SPECIFIC SOLUBLE SUBSTANCE BY PNEUMOCOCCUS DURING GROWTH.

Authors:  A R Dochez; O T Avery
Journal:  J Exp Med       Date:  1917-10-01       Impact factor: 14.307

  3 in total
  56 in total

1.  In memoriam. M. R. Irwin (1897-1987). Pioneer in immunogenetics.

Authors: 
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

2.  Development for Clinical Use of a Multiplexed Immunoassay Using Sputum Samples for Streptococcus pneumoniae: a Non-Culture-Based Approach for Serotype-Specific Detection.

Authors:  Sun Jin Kim; Yoo Jung Jeong; Jong Hun Kim; Young Kyung Yoon; Jang Wook Sohn; Moon Hee Nahm; Min Ja Kim
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

3.  A brief history of pneumococcal vaccines.

Authors:  R Austrian
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

Review 4.  Pneumococcal Capsules and Their Types: Past, Present, and Future.

Authors:  K Aaron Geno; Gwendolyn L Gilbert; Joon Young Song; Ian C Skovsted; Keith P Klugman; Christopher Jones; Helle B Konradsen; Moon H Nahm
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 5.  History of passive antibody administration for prevention and treatment of infectious diseases.

Authors:  Barney S Graham; Donna M Ambrosino
Journal:  Curr Opin HIV AIDS       Date:  2015-05       Impact factor: 4.283

6.  Interplay of Carbohydrate and Carrier in Antibacterial Glycoconjugate Vaccines.

Authors:  Tyler D Moeller; Kevin B Weyant; Matthew P DeLisa
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

7.  THE IMMUNOLOGICAL RELATIONSHIPS OF STREPTOCOCCUS VIRIDANS AND CERTAIN OF ITS CHEMICAL FRACTIONS : I. SEROLOGICAL REACTIONS OBTAINED WITH ANTIBACTERIAL SERA.

Authors:  R C Lancefield
Journal:  J Exp Med       Date:  1925-08-31       Impact factor: 14.307

8.  STUDIES ON IMMUNOLOGICAL RELATIONSHIPS AMONG THE PNEUMOCOCCI : III. RELATIONSHIP BETWEEN A VARIETY OF SACCHAROMYCES CEREVISIAE AND THE TYPE II VARIETY OF DIPLOCOCCUS PNEUMONIAE (PNEUMOCOCCUS).

Authors:  J Y Sugg; J M Neill
Journal:  J Exp Med       Date:  1929-01-31       Impact factor: 14.307

9.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : IV. THE SYNTHESIS OF THEp-AMINOBENZYL ETHER OF THE SOLUBLE SPECIFIC SUBSTANCE OF TYPE III PNEUMOCOCCUS AND ITS COUPLING WITH PROTEIN.

Authors:  W F Goebel; O T Avery
Journal:  J Exp Med       Date:  1931-07-31       Impact factor: 14.307

10.  ANTIPNEUMOCOCCIC IMMUNITY REACTIONS IN INDIVIDUALS OF DIFFERENT AGES.

Authors:  W D Sutliff; M Finland
Journal:  J Exp Med       Date:  1932-05-31       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.